MERIDIAN, Idaho, Nov. 8 /PRNewswire-FirstCall/ -- RxElite Holdings, Inc., a wholly- owned operating subsidiary of Southridge Technology Group, Inc. and a developer, manufacturer, and marketer of specialty generic prescription drug products, announced today that the Board of Directors approved the Company to change its name and trading symbol to RxElite, Inc. As of November 7, 2007, RxElite, Inc. is trading under the symbol RXEI on the OTC bulletin board.
“The name change is an important step in our branding as a public company. We are returning to the name that I founded the company under in 2000,” commented Jonathan Houssian, the CEO and founder of RxElite. “This is another key step in our plan to achieve significant year over year growth.”
About RxElite, Inc.
RxElite, Inc. develops, manufactures, and markets generic prescription drug products in specialty generic markets. These markets include products in the areas of anesthesia, sterile liquid dose drugs (including respiratory inhalation drugs, ophthalmics, and injectable drugs), and transdermal patch products.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 involving known and unknown risks, delays, and uncertainties that may cause our actual results or performance to differ materially from those expressed or implied by these forward-looking statements. These risks, delays, and uncertainties include, but are not limited to: risks associated with the uncertainty of future financial results, our reliance on our sole supplier, the limited diversification of our product offerings, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
investorrelations@rxelite.com
CONTACT: Corporate Information, +1-208-288-5550, Toll Free,
1-800-414-1901, Fax, +1-208-288-1191; or Investor Relations, Charlie
Forshee of Segue Ventures LLC, +1-215-885-4981,
investorrelations@rxelite.com, for RxElite Holdings, Inc.
Web site: http://www.rxelite.com/
